Anti-EGFR VHH-PS monovalent conjugates resulted in tumor necrosis in approximately 90% of tumor cells, which was significantly better than the mAbs Cetuximab-PS in an orthotropic mouse tumor model of head and neck cancer (82). This evidence concerns the gene EGFR and head and neck cancer.